Merck KGaA. (11/14/23). "Press Release: Merck Announces Plans for New U.S. Healthcare Headquarters in Boston’s Seaport District [Not intended for US-based media]". Darmstadt.

	Region	Boston, MA
	Country	United States (USA)
	Organisation	EMD Serono Inc.
	Group	Merck (DE) (Group)
	Organisation 2	Merck KGaA
	Group	Merck (DE) (Group)
	Product	pharmaceutical
	Product 2	real estate
	Person	Round, Chris (Merck (DE) 202311 President of EMD Serono)
	Person 2	Schrimpf, Gangolf (Merck (DE) 201708)

Not intended for US-based media

> The U.S. market is key to the company’s global Healthcare innovation strategy

> New location will be a critical driver for future therapeutic launches and help support current portfolio

Merck, which operates its Healthcare business as EMD Serono in the U.S. and Canada, today announced that it plans to move its U.S. Healthcare headquarters, currently located in Rockland, Mass., to Boston’s Seaport district.

“The U.S. market is critical to our continued success as a global specialty innovator. Today we deliver important therapeutic options to more than 150,000 oncology, multiple sclerosis (MS) and fertility patients in the U.S.,” said Chris Round, President of EMD Serono. “This move serves as an important milestone in our journey to bring further innovation to address high unmet medical needs in areas where patients rely on us. Our vibrant new office setting in the Seaport district will bring EMD Serono into the center of the globally leading healthcare innovation hub to support our future growth.”

The company plans to introduce one new product or major indication every 1.5 years on average, beginning with two potential U.S. launches in 2025. EMD Serono remains committed to optimizing its impact across three therapeutic areas – in Neurology & Immunology, Oncology, and Fertility, which includes:

2 available oncology products across 5 indications in the U.S.
20+ years of expertise in MS
25+ years of leadership in Fertility

The U.S. Healthcare business plans to move to 200 Pier 4 Boulevard in Boston’s Seaport district in summer 2024. In addition to the Seaport site, the Healthcare business will maintain its global Research and Development hub in Billerica, Mass.

The company is currently designing the offices in keeping with the Merck global footprint of inclusive, accessible, and sustainable workplaces that foster collaboration and support a variety of hybrid working arrangements. The company is targeting LEED and WELL certifications in its design in alignment with Merck’s sustainability goals.

For more information, please contact Gangolf Schrimpf
+496151729591
Email

All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck

Merck, a leading science and technology company, operates across life science, healthcare and electronics. More than 64,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2022, Merck generated sales of € 22.2 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.

Record changed: 2024-01-20